Not AIM. But still unforgiving, which I don't blame in this case. I'm very disappointed, given guidance from just a few weeks ago was 'We are confident in our immediate and long-term prospects' of hitting numbers. To be told, definitely won't hit numbers 3 weeks later is poor form on CH's/Management part, IMO.
I'm very confident that share price is currently way undervalued. The next few weeks and months this should really take off. It's a great entry point for anyone not invested.
I'm very confident that share price is currently way undervalued. The next few weeks and months this should really take off. It's a great entry point for anyone not invested.
For me, this is a massive positive as IDP will have more institutional holders. Wish the discount wasn't quite so much, but it could have been a lot worse. I'm happy with how he has put previous money to work, which has improved the business substantially. I expect the company will grow even further with this money, and institutional backing, behind it.
Im guessing someone wanted out and waited until there was a bit of volume to do so. Thankfully they waited and didnt dump when there were no buyers otherwise sp could have taken a big hit given low vol recently.
This should be trading between 3.0-4.0 by my model, which doesnt include the (hopefully positive) info to be released tomorrow. But it will correct itself in time, especially once they announce their profits. A CFO doesnt buy shares for no reason.
I'm surprised this dropped below 330 tbh. Guessing the traders are pulling out fearing a drop like Jan, which then becomes self fulfilling, and will pile back in once the knife has stopped falling. I'm confident that long term we'll look back on these levels as great buying opportunity...for those not already fully invested. People on adv are saying 260-280, but that's a laugh. Long term this one's a keeper.
Very positive RNS from my standpoint. Zinc is significantly undervalued according to my investment model.
'Not your typical AIM share', definitely! For one, it's listed on LSE not AIM. :-) For another it's got a strong product/brand, growing revenues and improving margins. Plus when it moves, it really moves. Good luck to those who try to time the market and trade this. For me, it's a long term hold.
Drop could be because investors are concerned about Sepura having "to discuss with its lenders a possible waiver of certain of its covenants from March 2017", as per half-year report RNS.
I've seen that BBC has commissioned a new program from Reef Products, a unit of Zinc Media, Getting the Builders In. It will be on in the morning(s) on BBC One. http://www.bbc.co.uk/mediacentre/latestnews/2017/new-daytime-commissions Combined with new commissions for "The Secret Life of" series, I'm expecting an extremely positive update soon.
If you check the latest report they have 700k cash on hand vs 100k a year ago. Sales are growing rapidly and the product wins awards. My investment model indicates a much higher sp and that we're under fair value at the moment. If you're looking for quick trade trader-mick, this one isn't for you. Medium-to-Long term, it's a great investment imo. But not one for an impatient trader. GL
https://indigo.bluematrix.com/indigo/Viewer.action?info=kK07jdZm7EHtXlURDJxHGID6RsvguY4a The Outlook reads positively for InnovaDerma. Superdrug has increased shelf space for Skinny Tan on average by a factor of four since January 2016, and H2 has started very strongly with January delivering the highest ever monthly sales in what is considered to be the slowest month in the self-tanning industry. Building the DTC platform remains a cornerstone of InnovaDerma’ s strategy which should help to maximise return on marketing spend. In a short period of 19 months, the Company has acquired in excess of 280,000 online community fans on Facebook. We have raised our FY17 revenue projections from £6.61m to £6.95m (y-o-y growth of 61.1%) and see scope for further upside given the new product launches and current momentum. We leave our profit forecasts unchanged reflecting some of the one offs incurred in H1 and the margin improvement the Company needs to deliver in H2 to achieve our projected PBT of £0.7m. Our forecasts imply a PEG Multiple of just 0.14x suggesting excellent value for the growth projected. The strong growth witnessed so far could be eclipsed if the US takes off, where online and terrestrial distribution deals are in place and initial orders have been secured. On an 18-month view, we continue to see the shares as capable of justifying a share price of over 207p.
Been reading the update in more detail now I have a bit more time this afternoon. It's chock full of some really nice nuggets! If people haven't already, I'd highly recommend taking the time to read the full report. It certainly seems like IDP is on a roll with more sales, profit growth and good news to come in multiple areas in 2017.
Welcome francobrett. Always nice to have another lth join in. While I'm expecting IDP to post a temporary loss for the interims, I'm also looking forward to some positive forward looking news tomorrow as well and hoping shareholders and the market will be well pleased with what IDP discloses. GLA!
With the Superdrug exclusivity presumably coming to an end soon and Michael Hume joining as General Manager, I expect we're seeing the calm before the storm here. Michael's remit is to expand and grow UK and European sales. Given he used to be a buyer at Tesco, I'd be surprised if we're not stocked in at least one of the multiples in due course. Hoping we'll get some clarification and positive forward-looking statements in the Interims. IMO this is a fantastic buying opportunity for a medium to long-term hold.
So Art, if Hybridan's target was 207p assuming a 53 rev increase, what do you think the target price is on 80% revenue growth?
Hybridan research note: Innovaderma: Fat Cheques For A Skinny Tan By Hybridan | 22/12/2016 InnovaDerma may not be a household name but its flagship brand Skinny Tan is making a splash in the beauty world, and since hitting the shelves of Superdrug in February 2016, became the number one tanning brand by revenue in July 2016 across the nationwide health and beauty chain’s 800 stores. Having come to light as a ‘Dragons’ Den’ investee company, the InnovaDerma team has given the brand a new lease of life, with a number of high profile distribution agreements across Australia, Europe, Asia and most recently North America. This commercial success has been borne out in recent financial results with Group revenue growing to A$8.5m in the year ending June 2016 vs just A$1.05m in FY2015 reflecting a 10-fold growth in revenue growth from Skinny Tan since its acquisition in May 2015. InnovaDerma also derives revenues from its Leimo brand of hair regeneration products (clinically proven hair loss treatment for men and women) and the entire range is being refreshed to coincide with the expected FDA approval of the company’s ‘Headmaster’ LED and laser helmet which is destined for the home use market. Our forecasts for the year ending June 2017 (to be reported in GBP) are projecting a 53% increase in revenues on a constant currency basis driven by the growing footprint of Skinny Tan. We have not assigned any growth to Leimo in this year. We also see improving margins driven not only by scale but also by the transfer of a significant amount of production to the UK which is due to result in a reduction in freight and logistics costs. Our forecasts suggest a 188% increase in operating profit to £699k and a 173% increase in EPS to 4.92p. Cashflow is likely to lag behind somewhat as the Company invests in working capital and inventory to support the strong rate of growth, but the recent fund raising activity should see the company through to operational cash generation. The shares are currently on a FYJun17 P/E multiple of c.30x and a price to sales multiple of 2.56x and therefore not without expectations of some success. However the Company has so far proved its ability to find and create winning brands. In terms of the plentiful recent acquisition activity in the space this is about mid-range with some parties paying up to 4 or 5 times revenues for niche brands. The multiples are not out of line with the quoted peer group either and a PEG analysis suggests that the shares offer good value for the earnings growth we are projecting in FY2017. With plenty of growth drivers to look forward to in 2018 we believe a share price of over 207p on an 18 month view is achievable.
Sorry Green. That sucks. Hope the next one works out better for you. GL.
For what it's worth, the broker forecasts are currently anywhere from 508-610 for the share price.